JasonConnor (@JasonConnorPhD) header
JasonConnor (@JasonConnorPhD) profile picture

President @ConfluenceStat Biostats consultant. Carnegie Mellon PhD. Texas A&M BS. UCF COM & Hopkins SPH prof. Coalminer's daughter's son.

Florida
Joined May 2013
Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)Photo by JasonConnor (@JasonConnorPhD)
Banner picture is my hometown, Barton MD, pop 457, far western Maryland.
1
15
Proud that my alma mater is putting a new campus near my home!
Today, Carnegie Mellon University and Ken Griffin, founder and CEO of Citadel and founder of Griffin Catalyst, announced a historic $3 billion gift to elevate Carnegie Mellon in Pittsburgh and launch Carnegie Mellon University Miami. #CMUMiami Learn more: cmu.edu/news/stories/archive…
1
114
As a statistician and huge tennis fan, this might be the best tweet ever.
When study PFS is positive but OS is not
3
1,476
Seven years ago, GBM AGILE set out to change how therapies for glioblastoma are developed. Today, that vision continues to gain momentum: • More than 2,600 patients have enrolled in study screening. • The platform has demonstrated its ability to evaluate therapies more efficiently while maintaining scientific rigor. • An eighth investigational arm is now active, expanding opportunities to learn faster and accelerate the development of potential new treatments. None of this would be possible without the patients, caregivers, investigators, research sites, industry partners, advocates, and other collaborators who continue to make GBM AGILE possible. In her latest letter, GCAR’s CEO & President Meredith Buxton reflects on seven years of progress, collaboration, and continued work as we remain committed to challenging convention and accelerating progress for patients. #GBMAGILE #Glioblastoma #GBM #ClinicalTrial #AdaptiveTrial #PlatformTrial #ClinicalResearch #BrainTumor #ResearchInnovation
2
3
387
Thrilled to participate in training young cardiologists for DMC work.
We’re honored to rename our DSMB training program the Bristow–DeMets DSMB Academy, recognizing the extraordinary contributions of Michael Bristow, MD, PhD and David DeMets, PhD to clinical trials, patient safety, and the generations of researchers they have inspired. #hfc
3
233
Thrilled to have co-authored and collaborated on this trial. Details here: jbjs.org/reader.php?rsuite_i…
Dr. Gerard Slobogean describes how orthopaedics is embracing adaptive platform trials and Bayesian analytics, with clinicians showing strong interest in structured, probability-based approaches. Weekly inquiries about new platform opportunities reflect a shift toward a learning health system—one where each answered question leads directly to the next, advancing patient-centered orthopaedic research. This environment fosters more structured trial activation and supports investigators in efficiently evaluating interventions. Gain more insights into this fascinating topic by listening to the latest episode of "In the Interim..." berryconsultants.com/resourc…
2
128
Episode 2 of "In the Interim..." with Berry Consultants is live! Join President, Dr. Scott Berry, and Director of Research, Dr. Kert Viele, as they unravel the nuances of adaptive design in clinical trials. Together they discuss integrating Bayesian approaches and optimizing adaptive designs to enhance learning and decision-making—key for efficient trials from phase 1 to phase 3. Also discover how adaptive trials help mitigate risks, save resources, and bring treatments to patients faster. Listen to the full conversation today: berryconsultants.com/podcast
7
34
2,854
Great podcast on the founding of my previous employer and adaptive designers extraordinaire, Berry.
To celebrate 25 groundbreaking years of innovation in statistical and clinical trial science, today we're excited to announce new branding, a new website, and the launch of Berry's "In the Interim..." podcast. In the inaugural podcast episode we sit down with founders, Donald Berry and Scott Berry, to hear their stories of Berry's journey, from pioneering Bayesian methodologies to actively shaping modern clinical trial designs. Discover how we overcame initial skepticism to bring about revolutionary change that benefits both pharmaceutical companies and patients worldwide. We’re on a mission to change the world, one trial at a time. See our new website, subscribe to our newsletter and podcast, and be part of our journey. berryconsultants.com berryconsultants.com/podcast #BerryConsultants #IntheInterimPodcast
2
543
My wife published this after her successful fight with triple negative breast cancer. Those who had their own cancer battles can probably relate. Those of us who haven’t can probably learn. medium.com/cancer-sucks-so-l…
1
4
1,139
Join our October edition of the RAR course & learn how it can help improve the design of your clinical trial! Register today: onlinesales.admin.cam.ac.uk/… Optional networking dinner has been added to the registration! @MRC_BSU
1
6
1
10
1,448
Anyone looking to learn more about Bayesian adaptive trials? I'm teaching a week long course in the Johns Hopkins summer institute June 24-28. @JohnsHopkinsSPH
6
7
1
18
7,132
The Least of Us by @samquinones7 is a fantastic book on those who quietly love, support, and do their best to help those enduring our drug epidemic, especially in Appalachia and the Rust Belt. Great people, great stories and a wonderful writer doing their work justice.
1
852
A scientist asking for evidence in good faith and reacting to evidence in good faith should never be censored and never be fired. We’d all be better off if more scientists had this level of courage and integrity.
2
896
Stats Q Group sequential trials look at X% of patients(info) for the final timepoint and calc the error spend. Is there an analogous group sequential method but you look at 100% of patients but at a 6m endpoint instead of 12m endpoint? Thanks!
3
1
3
1,722
Obviously you could just split alpha, 1% at 6m and 4% at 12m, but since the outcomes are likely to be correlated, it'd be nice to not have to 'spend' the full amount. With correlated 6m and 12m values, there would be more than 4% alpha 'left' at 12 months.
1
1
261
Congrats to my friend Kristine Broglio and Binbing Yu (and all of their contributors) for their new book!
1
2
409
Today I canceled my subscription to @TheAthletic (owned by @nytimes) and subscribed to The Free Press @TheFP As @bariweiss said, "There is no second America to run to if this one fails."
4
7
1
71
48,641
JasonConnor retweeted
I regret missing this gem from @US_FDA on Bayesian hierarchical models. This article discusses shrinkage estimation for subgroups. Hierarchical models are fundamental to basket trials, meta-analyses, historical borrowing, and many other RCT applications. fda.gov/drugs/regulatory-sci…
12
1
40
7,015